2,2-diethyl-valeric acid amide | 102450-22-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2,2-diethyl-valeric acid amide
• 英文别名: 2,2-Diaethyl-valeriansaeure-amid；2,2-Diethyl-2-propyl-acetamid；2,2-Diethylpentanamide
• CAS: 102450-22-6
• 化学式: C₉H₁₉NO
• 分子量: 157.256
• InChiKey: HMSZBVWINUSBDQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2,2-diethyl-valeric acid amide 在 盐酸 、 氯化亚砜 、 亚硝酸丁酯 、 溶剂黄146 作用下， 生成 2,2-diethylpentanoyl chloride
  参考文献：
  名称：

  Murayama, Chemical and pharmaceutical bulletin, 1958, vol. 6, p. 186,190

  摘要：

  DOI：
• 作为产物：
  描述：

  2,2-diethyl-1-phenyl-pentan-1-one 在 sodium amide 、 苯 作用下， 生成 2,2-diethyl-valeric acid amide
  参考文献：
  名称：

  Carter; Slater, Journal of the Chemical Society, 1946, p. 132

  摘要：

  DOI：

文献信息

• [EN] TARGETING OCULAR DISEASES WITH NOVEL APE1/REF-1 INHIBITORS<br/>[FR] CIBLAGE DE MALADIES OCULAIRES AVEC DE NOUVEAUX INHIBITEURS APE1/REF-1
  申请人：UNIV INDIANA RES & TECH CORP

  公开号：WO2019157163A1

  公开（公告）日：2019-08-15

  [(2E)-2-[(3-methoxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)methylidene]-N,N-diethylpentanamide] (APX2009) and (2E)-2-[(3-methoxy-1,4-dioxo-1,4-dihydronapthalen -2-yl)methylidene]-N-methoxypentanamide] (APX2014) for inhibiting ocular diseases are disclosed herein.

  本文披露了用于抑制眼部疾病的[(2E)-2-[(3-甲氧基-1,4-二氧杂-1,4-二氢萘-2-基)甲亚甲基]-N,N-二乙基戊酰胺]（APX2009）和[(2E)-2-[(3-甲氧基-1,4-二氧杂-1,4-二氢萘-2-基)甲亚甲基]-N-甲氧基戊酰胺]（APX2014）。
• USE OF APE1/REF-1 INHIBITORS IN COMBINATION THERAPIES FOR TREATMENT OF CANCER
  申请人：Indiana University Research & Technology Corporation

  公开号：EP3430057A1

  公开（公告）日：2019-01-23
• EP3749633A1
  申请人：——

  公开号：EP3749633A1

  公开（公告）日：2020-12-16
• [EN] USE OF APE1/REF-1 INHIBITORS IN COMBINATION THERAPIES FOR TREATMENT OF CANCER<br/>[FR] UTILISATION D'INHIBITEURS D'APE1/REF-1 DANS DES POLYTHÉRAPIES POUR LE TRAITEMENT DU CANCER
  申请人：UNIV INDIANA RES & TECH CORP

  公开号：WO2018175429A1

  公开（公告）日：2018-09-27

  Combination therapies including a Apurinic/Apyrimidinic Endonuclease/reduction-oxidation (redox) Factor-1 (APE1/Ref-1) inhibitor specific to inhibit the redox function of APE1/Ref-1 are disclosed herein. The Combination therapies can be used for treating various cancers, as well as other angiogenesis-mediated diseases (e.g., retinal diseases, cardiovascular diseases).
• [EN] METHODS FOR SEPARATION AND RECOVERY OF RARE EARTH ELEMENTS FROM AQUEOUS SOLUTIONS USING DIGLYCOLAMIDE DERIVATIVES<br/>[FR] PROCÉDÉS DE SÉPARATION ET DE RÉCUPÉRATION D'ÉLÉMENTS DE TERRES RARES CONTENUS DANS SOLUTIONS AQUEUSES FAISANT APPEL À DES DÉRIVÉS DE DIGLYCOLAMIDE
  申请人：UT BATTELLE LLC

  公开号：WO2022010759A2

  公开（公告）日：2022-01-13

  A method for extracting rare earth elements from aqueous solution, comprising: (i) acidifying an aqueous solution containing said rare earth elements with an inorganic acid to result in an acidified aqueous solution containing said rare earth elements and containing the inorganic acid in a concentration of 1-12 M, wherein said rare earth elements are selected from lanthanides, actinides, or combination thereof; and (ii) contacting the acidified aqueous solution with an aqueous-insoluble hydrophobic solution comprising a rare earth extractant compound dissolved in an aqueous-insoluble hydrophobic solvent to result in extraction of one or more of the rare earth elements into the aqueous-insoluble hydrophobic solution by binding of the rare earth extractant compound to the one or more rare earth elements, wherein the rare earth extractant compound has the structure of Formula (1) provided that at least one of the conditions (a)-(d) applies.